

Mitchell F Brin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3348267/publications.pdf>

Version: 2024-02-01

16
papers

1,270
citations

840776

11
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

992
citing authors

#	ARTICLE	IF	CITATIONS
1	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-blind, Randomized, Placebo-controlled Phases of the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 921-936.	3.9	779
2	Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?. <i>Cephalalgia</i> , 2016, 36, 875-886.	3.9	101
3	Pooled Analysis of the Safety of Botulinum Toxin Type A in the Treatment of Poststroke Spasticity. <i>Archives of Physical Medicine and Rehabilitation</i> , 2006, 87, 786-792.	0.9	76
4	Botulinum toxin type A products are not interchangeable: a review of the evidence. <i>Biologics: Targets and Therapy</i> , 2014, 8, 227.	3.2	70
5	Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30-year experience. <i>Laryngoscope</i> , 2018, 128, S1-S9.	2.0	51
6	Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection. <i>Neuroscience</i> , 2017, 352, 155-169.	2.3	49
7	The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial. <i>EClinicalMedicine</i> , 2020, 24, 100429.	7.1	44
8	Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. <i>Journal of Drugs in Dermatology</i> , 2011, 10, 39-44.	0.8	28
9	Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. <i>Cephalalgia</i> , 2019, 39, 1358-1365.	3.9	27
10	Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. <i>Cephalalgia</i> , 2021, 41, 17-32.	3.9	20
11	Atogepant "an orally-administered CGRP antagonist" attenuates activation of meningeal nociceptors by CSD. <i>Cephalalgia</i> , 2022, 42, 933-943.	3.9	12
12	Negative dystonia of the palate: A novel entity and diagnostic consideration in hypernasal speech. <i>Laryngoscope</i> , 2015, 125, 1426-1432.	2.0	4
13	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. <i>Cephalalgia</i> , 2022, , 033310242210998.	3.9	3
14	OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood-brain barrier. <i>Pain</i> , 2021, 162, 2418-2427.	4.2	2
15	Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA. <i>Toxins</i> , 2020, 12, 661.	3.4	1
16	Reply. <i>Dermatologic Surgery</i> , 2014, 40, 1419-1420.	0.8	0